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Abstract 
Nestin,  an  intermediate  filament  protein,
has traditionally been noted for its importance
as  a  neural  stem  cell  marker.  However,  in
recent years, expression of nestin has shown
to be associated with general proliferation of
progenitor cell populations within neoplasms.
There is no reported study addressing nestin
expression in T4 breast cancer patients. Thus,
the aim of the present study was to investigate,
through  immunohistochemistry,  the  expres-
sion and distribution of nestin in T4 breast
cancer, in order to determine its association
with clinical and pathological parameters as
well  as  with  patients’  outcome.  Nestin  was
detectable in tumoral cells and in endothelial
cells of blood microvessels, and it is signifi-
cantly  expressed  in  triple-negative  and  in
inflammatory breast cancer (IBC) subgroups
of T4 breast tumours. The Kaplan-Meier analy-
sis  showed  that  the  presence  of  nestin  in
tumoral cells significantly predicted poor prog-
nosis  at  5-years  survival  (P=0.02)  and  with
borderline significance at 10-years of survival
(P=0.05) in T4 breast cancer patients. On the
basis of these observations, we speculate that
nestin expression may characterize tumours
with an aggressive clinical behavior, suggest-
ing that the presence of nestin in tumoral cells
and vessels may be considered an important
factor that leads to a poor prognosis. Further
studies  are  awaited  to  define  the  biological
role  of  nestin  in  the  etiology  of  these  sub-
groups of breast cancers.
Introduction
Among all the potentially useful prognostic
biomarkers,  the  International  Union  Against
Cancer (UICC)/American Joint Committee on
Cancer (AJCC) TNM staging system,1 incorpo-
rates only tumor thickness, nodal status, and
presence of distant metastase because, in the
most of the other clinicopathologic prognostic
factors, there aren’t reproducible definitions,
easy applicable, and they are lacking of agree-
ment among the world’s experts. According to
this  system,  primary  breast  cancers  with
extension to the skin are classified as T4, and
patients with T4 carcinomas of any type, with
or without lymph node involvement, and with-
out distant metastases (T4 N0-2 M0), are clas-
sified as disease stage IIIB. Primary breast car-
cinomas infiltrating skin or chest wall (T4 a-
c), as well as inflammatory breast carcinoma
(T4d, IBC), are included in locally advanced
breast cancer (LABC) group.1,2 In addition to
the tumour size and the axillary lymph node
involvement, other well-established prognostic
factors currently used in breast cancer include
histological subtype or grade, estrogen (ER)
and progesterone (PR) receptor status, HER2
amplification, and Ki67 proliferation index.3,4
LABC  remains  a  clinical  challenge  as  the
majority of patients with this diagnosis devel-
op  distant  metastases  despite  appropriate
therapy.5 The molecular mechanisms underly-
ing LABC are largely unknown. Identification
of these may contribute to develop new thera-
pies that can arrest local invasion and metasta-
tic spread of the disease.
Nestin,  an  intermediate  filament  protein,
has traditionally been noted for its importance
as a neural stem cell marker.6,7 However, in
recent years, expression of nestin has shown
to be associated with general proliferation of
progenitor cell populations within neoplasms.
Several studies have thus targeted nestin as a
potential diagnostic and prognostic marker of
brain malignancy.8,9 Upregulation of nestin is
also  closely  associated  with  malignancy  and
metastasis of other types of cancer outside of
the  brain  such  as  melanoma,10 colorectal,11
prostate,12 and pancreatic cancer.13 In breast
cancer, nestin expression was evaluated in T1,
T2,  and  T3  breast  carcinomas14-18 and  was
found  preferentially  in  triple  negative  and
basal like phenotype of these tumours. These
findings substantiate the possibility of using
nestin as a marker for triple-negative pheno-
type of T1, T2, and T3 breast carcinomas but,
currently, there is no reported study address-
ing  nestin  expression  in  T4  breast  cancer
patients. 
A distinct gene-expression profile has been
described for T3/T4 tumours in comparison to
the  gene-expression  pattern  of  T1/T2
tumours,19 suggesting that a distinct biological
behaviour may characterize initial vs. locally
advanced breast carcinomas.20,21
In the light of these findings, in the present
study we examined the expression of nestin in
a well-characterized cohort of patients with T4
breast carcinoma and a long follow-up, in order
to determine its association with clinical and
pathological  parameters  as  well  as  with
patients’ outcome.
Materials and Methods
Patients and tissue specimens
Paraffin-embedded  samples  of  53  patients
with T4 breast cancer were included into the
study. Cases were enrolled between 1992 and
2001, and observed up to September 2008 for a
median  of  125  months  (range,  82-194).
Patients were assessed by physical examina-
tion and mammography, confirmed via core-
needle biopsy. Of 13 patients both core-needle
biopsy and surgical specimen were available.
All patients completed a treatment plan includ-
ing primary chemotherapy, surgery, radiation
therapy, adjuvant chemotherapy, and hormone
therapy,  when  indicated  (see  below).  The
median  age  was  51  years  (range,  32-67).
Baseline  characteristics  are  summarized  in
Table  1.  According  to  the  American  Joint
Committee  on  Cancer  (AJCC)  TNM  staging
system,1 all 53 cases included into this study
were classified with the highest stage of non-
metastatic disease (Stage IIIB). Estrogen (ER)
and progesterone (PR) status was assessed by
standard  immunohistochemistry;  nuclear
staining  in  ≥10%  was  considered  positive
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(according to the indication that a significant
difference  in  5-year  recurrence-free  survival
between ER-positive and ER-negative patients
has been reported for a cut-off of 10%).22 HER2
status  was  assessed  by  fluorescence  in  situ
hybridization (FISH) analysis. The study was
approved by the Institutional Review Board at
the University of Cagliari. A written informed
consent was obtained for using tissue speci-
mens in molecular analyses.
Treatment plan
All  patients  were  treated  with  primary
chemotherapy using anthraceyline-containing
regimens,  such  as  FEC  (5-Fluorouracil;
Epirubicin;  Cyclophosphamide)  or  PEV
(Cisplatin;  Epirubicin;  Vinorelbine).  After
completing  the  neoadjuvant  chemotherapy,
patients underwent surgery consisting of mod-
ified radical mastectomy (MRM) or breast-con-
serving surgery (BCT). Postoperative adjuvant
chemotherapy consisted of six cycles of CMF
(cyclophosphamide,  methotrexate,  fluo-
rouracil). Locoregional radiotherapy was per-
formed during the fourth course of CMF. After
completing  adjuvant  chemotherapy,  patients
with  hormone  receptor-positive  tumours
received tamoxifen for 5 years. Clinical evalu-
ations were performed every 3 months for 2
years  and  every  6  months  thereafter.
Instrumental examinations (e.g., mammogra-
phy, liver ultrasound, chest X-ray, bone scan,
and echocardiogram) were performed every 6
months  for  the  first  2  years,  and  every  12
months thereafter.
Response assessment
The clinical measurement of the response to
neoadjuvant therapy was defined according to
the  International  Union  Against  Cancer
(UICC)  criteria.23 Pathological  complete
response (pCR) was defined as the histological
absence of residual invasive disease in both
the breast and the axilla. Presence of histolog-
ical invasive residual disease in breast tissue
or detection of cancer-positive lymph nodes in
the axilla were defined as <pCR. Major patho-
logical response (MpR) in breast tissue was
defined as no more than 2 cm of residual dis-
ease (pT0 plus pT1).24
Immunohistochemistry
Serial microtome sections, 5 µm thick, were
treated  immunohistochemically  for  nestin
antigen, and for endothelial cell marker CD31
using  the  alkaline  phosphatase-streptavidin
method.  Heat-induced  antigen  retrieval  was
performed at 95°C for 40 min in 10 mM citrate
buffer solution (pH 6.0), for CD31. No antigen
retrieval was used for nestin immunostaining.
Non-specific  binding  was  blocked  with  10%
normal goat serum for nestin immunostain-
ing,  or  with  normal  horse  serum  for  CD31
immunostaining,  for  45  min.  Mouse  mono-
clonal  antibodies  against  nestin  (Novus
Biologicals,  Littleton,  CO,  USA;  clone  10C2;
1:500 dilution), and mouse monoclonal anti-
bodies  to  human  CD31  (Dako,  Glostrup,
Denmark;  clone  JC70A;  1:50  dilution)  were
used  as  primary  antisera.  Alkaline  phos-
phatase (AP) conjugated anti-mouse antibod-
ies (Chemicon Int., Temecula, CA, USA; 1:200
dilution) were used as secondary antisera in
nestin  immunostaining.  Biotinylated  anti-
mouse IgG were used as secondary antisera
(Vector  Laboratories,  Burlingame,  CA,  USA;
1:1000  dilution)  for  CD31  immunostaining,
and  the  sections  were  further  incubated  in
alkaline  phosphatase-streptavidin  (Vector
Laboratories,  1:1000  dilution).  Liquid
Permanent  Red  (LPR)  substrate-chromogen
system (Dako) was used to develop the APase
reaction  product.  Negative  controls  were
established by replacing the primary antibod-
ies with normal serum. Melanoma specimen,
which strongly expressed nestin was used as
positive control for nestin immunostaining.
To confirm that nestin positive microvessels
were blood vessels, nestin and CD31 immunos-
taining  were  performed  using  serial  tissue
sections.
Slides were viewed using microscope Zeiss
Axiophot  (Carl  Zeiss  Inc.,  Oberkochen,
Germany). The entire tumor of each case was
microscopically examined through 200X mag-
nification fields with a 144-intersection point
square reticulum (0.78 mm2) inserted in the
eyepiece to count nestin immunoreactive cells
of whole tumor, and the average of this counts
was considered. Nestin expression was evalu-
ated  by  three  of  the  authors  (FP,  SL,  PS)
according to the following criteria: cases with
<10%  of  discrete  cytoplasmic  expression  in
morphologically  unequivocal  neoplastic  cells
were  classified  as  negative  and  cases  with
≥10%  of  discrete  cytoplasmic  expression  in
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Table 1. Tumor characteristics and clinical variables: association with nestin expression
and with overall survival.
N. of patients Nestin P* N. of events P°
Age  0.276 0.541
≤51# 25 11 15
>51 28 17 15
Tumor stage 0.016 0.455
T4abc 38 16 21
T4d 15 12 9
Axillary nodes§  1.000 0.029
cLN 0 12 63
cLN + 41 22 27
Triple negative 0.002 0.039
Yes 18 15 13
No 35 13 17
Hormone receptor status 0.029 0.140
ER - PR- 24 17 16
ER - PR + 11 0
ER + PR - 12 66
ER + PR + 16 48
Estrogen receptor status 0.013 0.075
ER+ 28 10 14
ER - 25 18 16
Progesteron receptor status 0.037 0.079
PR + 17 58
PR - 36 23 22
HER2 status 0.162 0.635
HER2 + 10 35
HER2 - 43 25 25
Grading 0.360 0.461
G2 38 22 23
G3 15 67
Pathological response 0.255 0.087
pCR 85 2
<pCR 45 23 28
Clinical response 0.256 0.043
Complete response 84 2
Partial response 36 17 20
< Partial response 97 8
*Fisher’s exact test or Pearson’s test; °log-rank test; #median age; §after primary chemotherapy.[European Journal of Histochemistry 2011; 55:e39] [page 217]
morphologically  unequivocal  neoplastic  cells
were considered to be positive.
Statistical analysis
Pearson’s and Fisher’s exact tests were used
to  evaluate  possible  associations  between
covariates such as nestin expression, ER, PR,
HER2 and clinical outcome in terms of treat-
ment responses, and to evaluate a correlation
of nestin expression with clinicopathological
variables as age, grading, axillary lymph node
metastasis, hormon receptor status, and HER2
status. Univariate correlations between prog-
nostic variables and overall survival were car-
ried  out  using  the  Kaplan-Meier  method.
Comparisons  were  made  using  the  log-rank
test. Overall patient survival rates were calcu-
lated  from  the  date  of  initial  primary
chemotherapy to the date of death caused by
breast  cancer,  or  last  follow-up,  until
September 2008. Data on patients who died of
other  causes  were  censored  at  the  time  of
death. Statistical comparisons were performed
using the SPSS Statistical Package for Social
Science, version 15.0 (SPSS Inc., Chicago, IL,
USA). All tests were two-tailed and P values of
less than 0.05 were considered to be statistical-
ly significant.
Results
Immunohistochemistry
Nestin was expressed in a wide variety of
cells, including tumor cells, endothelial cells of
blood  microvessels,  basal  cells  of  apparently
normal  mammary  glands,  and  in  cells  with
fibroblast morphology in the peritumoral stro-
ma  (Figure  1),  especially  surrounding  both
ductus  and  vessels.  CD31  expression  was
found in vascular endothelial cells and in scat-
tered cells of all cases.
When nestin expression was detected at the
periphery of ducts or/and in vessels, or/and in
peritumoral stroma, but not in the tumor itself,
the tumors were scored as negative. Positivity
for nestin was defined as detectable expres-
sion within the tumor and not merely at the
periphery of the tumor. For example, a carcino-
ma  in  which  the  intact  basal/myoepithelial
layer stains positive but the cells within the
core of the carcinoma do not, would be scored
as negative. The tumors were scored as posi-
tive only when nestin expression was detected
in tumor cells.
Statistical analysis
Cases with more than 10% of tumor cells
positive  for  nestin  included  53%  of  cases
examined. All cases showed nestin expression
in scattered cells and in endothelial cells of
microvessels. Seventy percent of cases showed
nestin expression in cells with fibroblasts mor-
phology.   No change in expression of nestin
was found between core-needle biopsies and
surgical specimens in the 13 cases for which
both samples were available.
Using  Pearson’s and  Fisher’s  exact  tests,
nestin expression was evaluated for associa-
tion  with  histological  tumour  characteristics
and/or  with  clinical  variables  (Table  1).
Statistical  difference  was  found  in  nestin
expression  between  inflammatory  and  non
inflammatory  group  of  patients  (P=0.016).
Among patients who had initially inflammato-
ry breast carcinoma (T4d), 80% were nestin
positive.  Nestin was mostly expressed in triple
negative  tumours  respect  to  those  no  triple
negative. Results indicate that in 83% of triple-
negative tumors, nestin expression was readi-
ly  detectable  (P=0.002).  The  association
between hormone receptor status and nestin
expression  was  statistically  significant
(P=0.029): 25% of cases with luminal pheno-
type (ER+, PR+) were nestin positive, where-
as 71% of cases with complete negative hor-
mone receptor status (ER-, PR-) were nestin
positive.  The  association  between  estrogen
receptor status and nestin expression showed
that  72%  of  ER-  cases  were  nestin  positive
(P=0.013).  The association between proges-
teron  receptor  status  and  nestin  expression
showed that 64% of PR- cases were nestin pos-
itive  (P=0.037).  No  association  between
nestin tumoral cells expression and age, axil-
lary lymph node metastasis, HER2 status, grad-
ing,  pathological  or  clinical  response  to  pri-
mary  neoadjuvant  therapy  was  observed.  No
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Figure  1.  Immunohistochemical  staining  of  nestin  in  breast  cancer.  A,B)  nestin-
immunoreactivity  was  found  in  myoepithelium  of  the  apparently  normal  mammary
glands adiacently to tumoral mass (internal positive control); C), presence of cytoplasmic
nestin expression in tumoral cells of a T4b breast cancer case with ER+, PgR+, HER2-
phenotype. D), presence of nestin expression in tumoral cells of a T4d inflammatory
breast cancer case with ER+, PgR-, HER2- phenotype; E), presence of nestin expression in
tumoral cells of aT4d inflammatory breast cancer case with ER-, PgR-, HER2- triple-neg-
ative phenotype. F), intense nestin immunoreactivity in endothelial cells of peritumoral
stroma. Original magnification: x400 (A); x1000 (B, D); x630 (C, E, F).[page 218] [European Journal of Histochemistry 2011; 55:e39]
correlation  between  tumoral  cells  nestin
expression  and  stromal  cells  with  fibroblast
morphology  nestin  expression  was  observed
(P=1). Particularly, stromal nestin expression
was  found  in  12  of  18  triple  negative  cases
(67%) and in 8 of 15 inflammatory breast can-
cer cases (53%). No statistical association was
found between stromal nestin expression and
triple negative phenotype (P=0.77) or inflam-
matory breast cancer (P=0.53).
In the same table is also observable that,
among clinicopathological factors, only nodal
involvement, triple negative status, and clini-
cal response to primary chemotherapy signifi-
cantly  correlated  with  survival  (P<0.05)  by
Kaplan-Meier method. 
The Kaplan-Meier analysis showed that the
presence of nestin in tumoral cells significant-
ly predicted poor prognosis at 5-years survival
(Figure 2; P=0.02) and with borderline signifi-
cance  at  10-years  of  survival  (Figure  3;
P=0.05)  in  patients  with  T4  breast  cancer,
while after 10-years survival nestin presence
lost its prognostic value (P=0.09). Statistical
data are showed in Table 2.
Discussion
In the present study, we evaluated the distri-
bution  of  nestin  expression  in  T4  breast
tumours and the impact of this protein expres-
sion as predictive and prognostic factor among
patients with T4 breast carcinoma. 
Nestin staining was interpretable in more
than half of examined tumours, and its expres-
sion  correlated  with  inflammatory  and  hor-
mone receptor status. 
Inflammatory breast cancer is a specific and
aggressive form of LABC, characterized by an
elevated metastatic and angiogenic potential,25
and by poor prognosis.26,27 It was demonstrated
that IBC shows a distinct gene-expression pro-
file  compared  to  non-IBC.19 In  the  study  of
Bertucci  et  al.,  as  compared  with  the  group
rich in NIBC, the group of tumours rich in IBC
exhibited  overexpression  of  the  basal,  the
immune, and the vascular gene clusters and
underexpression  of  the  luminal  cluster.26
These expression changes were in agreement
with  the  phenotypical  characteristics  of  IBC
and NIBC, and suggest that IBC is related to
the  basal  lineage  more  frequently  than  is
NIBC.26,27 The IBC cases of the present study
showed a strong difference in expression of
nestin compared to non-IBC, with 80% of IBC
positive for nestin expression. A recent study
reported  co-expression  of  nestin  and  mela-
tonin receptor 1 (MT 1) in patients with high-
er  tumor  stages  (TII/III),  signifying  that  co-
expression of nestin and MT 1 may correlate
with  invasive  breast  cancer  and  advanced
tumors.15 Lymphovascular emboli of inflamma-
tory breast cancer, characterized by exaggerat-
ed lymphovascular invasion, express stem cell
markers, including nestin.28,29 Our results con-
firm these data and indicate that nestin corre-
lates  with  an  aggressive  growth  phenotype.
This stem cell-like phenotype, characterized by
strong expression of many angiogenesis mark-
ers,28 including nestin, may contribute to the
aggressive nature of IBC by a metastatic mech-
anism in which an increased number of tumor
vessels increases the chances for tumor cells
to enter the circulation. Newly formed tumor
vessels  or  capillaries  have  leaky  and  weak
basement membranes; thus, tumor cells can
penetrate  these  more  easily  than  they  can
mature vessels. 
In the current study, nestin was observed in
endothelial cells of numerous microvessels in
all cases. In agreement to various reports, indi-
cating nestin as angiogenesis marker for pro-
liferating endothelial cells in many cancer tis-
sues,10,30-32 our results show nestin staining as
indicator of newly formed endothelial cells and
of an remarkable involvement of this protein in
angiogenesis  and  vasculogenesis  of  breast
cancer. 
Recent studies evaluated nestin distribution
in different receptor phenotypes of T1, T2 and
T3 breast tumours. Nestin was found highly
expressed  in  basal  breast  cancer  subtype
(ERα-/PR-/Her2-) but not in the Her2 subtype
(ERα-/PR-/Her2+) or luminal epithelial pheno-
type  (ERα+/PR+).16 According  these  data,  a
recent study showed that triple-negative breast
cancers  have  higher  expression  rates  for
nestin  than  other  breast  cancers.18 Another
study  has  reported  significantly  high  nestin
expression  in  basal-like  and  triple  negative
breast  cancers  in  a  cohort  of  patients  with
invasive breast cancer treated with surgery fol-
lowed by anthracycline-based chemotherapy.17
In the present study, nestin was found prefer-
entially  expressed  in  triple  negative  breast
tumours and correlated with lack of ER and PR,
while it was poorly expressed in  luminal phe-
notypes.  These  data  support  precedent  find-
ings and, although the involvement of nestin
in molecular mechanisms of triple negative is
still unclear, they indicate that nestin may be a
selective marker of triple negative phenotype
and the basal breast cancer subtype, that dis-
play  an  aggressive  growth  and  have  a  poor
prognosis  in  stage  IIIB  T4  locally  advanced
breast tumours.
Breast  tumours  are  histologically  complex
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Table 2. Estimated 5- and 10-year survival rates for T4 breast cancer patients with different nestin expression
Patients Events 5-years % 5-year survival (SE) P* Events 10-years % 10-year survival (SE) P*
Nestin  0.02 0.05
Negative 25 6 76.0 (8.5) 10 51.0 (12.8)
Positive 28 15 46.4 (9.4) 19 28.1 (9.4)
*Log-rank-test.
Figure  2.  Kaplan-Meier’s  5-year  survival
curves according to immunoreactivity for
nestin protein of patients with T4 breast
cancer (P=0.02).
Figure 3. Kaplan-Meier’s 10-year survival
curves according to immunoreactivity for
nestin protein of patients with T4 breast
cancer (P=0.05).[European Journal of Histochemistry 2011; 55:e39] [page 219]
tissues, containing a variety of cell types in
addition  to  the  carcinoma  cells,  such  as
endothelial  cells,  adipose-enriched/normal
breast cells, B, T lymphocytes, macrophages,
and stromal cells. In our study, in peritumoral
stroma, cells with fibroblast morphology were
positive for nestin. This is an important find-
ing, since it has become increasingly evident
that epithelial-stromal interactions are crucial
to tumor development and fibroblasts in the
tumor  microenvironment  are  involved  in
angiogenesis, growth and invasion.33-35
Furthermore,  nestin  expression  has  been
associated with shorter survival and shown to
be an independent prognostic factor of breast
cancer.18 Our findings indicated that this sub-
set of T4 breast cancer patients with nestin
expression in primary tumour tissues present-
ed a worse overall 5- and 10-years survival rate
respect  to  cases  without  nestin  expression.
Since  an  increased  expression  of  nestin  in
tumour tissues has been already demonstrated
to correlate with a poor clinical outcome in a
variety  of  malignancies,28 our  results  clearly
indicated an analogous significant impact on
prognosis  of  such  a  molecular  alteration
among  T4  breast  cancer  patients.  In  fact,
although the role of nestin in breast cancer
has not been well characterized, there is evi-
dence to suggest that this protein may play a
role  in  the  regulation  of  mitosis16,36,37 and
tumour  invasiveness.38 Among  histological-
clinical variables evaluated, only triple nega-
tive status and nodal involvement, and clinical
response  after  primary  chemotherapy  were
significantly  correlated  with  overall  survival.
The role of these variables as prognostic and
predictive factors is already well defined, how-
ever, the assessment of additional biomarkers
strictly related to tumour cell biology, as nestin,
could improve the accuracy of diagnosis or risk
assessment  to  guiding  selection  of  optimal
therapeutic  interventions  in  support  of  the
paradigm  shift  towards  more  personalized
medicine.
In our study, nestin expression doesn’t seem
to be significantly correlated with response to
primary chemotherapy; however, note worthy
is  that  no  change  in  nestin  expression  was
found between core-needle aspirates and sur-
gical specimens of the same patient. 
In summary, our findings show that nestin
is  consistently  expressed  in  triple-negative
and  in  IBC  subgroups  of  T4  breast  cancer.
Nestin  expression  may  characterize  tumors
with an aggressive clinical behavior, suggest-
ing that the presence of nestin in tumoral cells
and vessels can be considered an important
factor that leads to a poor prognosis. To vali-
date the incorporation of nestin as marker for
management of these tumours, further large
prospective  studies  are  awaited.  Improved
understanding of the etiology of these tumours
may  help  to  identify  selective  markers  and
therapeutic targets that will improve detection,
diagnosis, and treatment of breast carcinomas. 
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